Cargando…
Targeting CD47 for cancer immunotherapy
Much progress has been made in targeting CD47 for cancer immunotherapy in solid tumors (ST) and hematological malignancies. We summarized the CD47-related clinical research and analyzed the research trend both in the USA and in China. As of August 28, 2021, there are a total 23 related therapeutic a...
Autores principales: | Jiang, Zhongxing, Sun, Hao, Yu, Jifeng, Tian, Wenzhi, Song, Yongping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8557524/ https://www.ncbi.nlm.nih.gov/pubmed/34717705 http://dx.doi.org/10.1186/s13045-021-01197-w |
Ejemplares similares
-
Research progress on dendritic cell vaccines in cancer immunotherapy
por: Yu, Jifeng, et al.
Publicado: (2022) -
IMM0306, a fusion protein of CD20 mAb with the CD47 binding domain of SIRPα, exerts excellent cancer killing efficacy by activating both macrophages and NK cells via blockade of CD47-SIRPα interaction and FcɣR engagement by simultaneously binding to CD47 and CD20 of B cells
por: Yu, Jifeng, et al.
Publicado: (2022) -
Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy
por: Cao, Weijie, et al.
Publicado: (2022) -
IMM47, a humanized monoclonal antibody that targets CD24, exhibits exceptional anti-tumor efficacy by blocking the CD24/Siglec-10 interaction and can be used as monotherapy or in combination with anti-PD1 antibodies for cancer immunotherapy
por: Li, Song, et al.
Publicado: (2023) -
Crystal Structure of Human CD47 in Complex with Engineered SIRPα.D1(N80A)
por: Yu, Jifeng, et al.
Publicado: (2022)